{"hypothesis_title": "TREM2-Dependent Microglial Senescence Transition","synthesis_summary": "This hypothesis proposes that TREM2 loss-of-function in microglia triggers metabolic dysregulation leading to cellular senescence and subsequent neurodegeneration. While TREM2 genetic variants strongly associate with increased AD risk (3-fold), the causal chain from TREM2 dysfunction to senescence remains inferential rather than mechanistically demonstrated. Antibody-based targeting of TREM2 is technically feasible but represents an expensive, high-risk approach with AL002 already in Phase 2 trials.","scores": {"mechanistic_plausibility": 0.62,"evidence_strength": 0.55,"novelty": 0.70,"feasibility": 0.52,"therapeutic_potential": 0.65,"druggability": 0.45,"safety_profile": 0.58,"competitive_landscape": 0.50,"data_availability": 0.52,"reproducibility": 0.60},"composite_score": 0.57,"key_strengths": ["Strong human genetic evidence linking TREM2 loss-of-function to 3-fold increased AD risk","TREM2 is a validated microglial receptor with known signaling pathways (DAP12/SYK/PI3K/AKT)","Provides a testable framework connecting metabolism, senescence, and neurodegeneration","Proposes a distinct mechanism beyond impaired phagocytosis"],"key_weaknesses": ["Causality chain relies on inference rather than demonstrated mechanisms","Senescence is one of several downstream consequences of TREM2 dysfunction","TREM2 is an extracellular receptor limiting small-molecule approaches","Antibody-based programs are expensive and technically demanding","Competing explanations for TREM2's role remain viable"],"top_predictions": ["TREM2 loss will cause measurable metabolic defects (reduced glucose uptake, mitochondrial dysfunction) in patient-derived microglia","SA-β-gal+ microglia will be detectable in AD brain tissue and correlate with TREM2 expression levels","TREM2 agonist treatment will reduce senescence markers in disease models"],"recommended_next_steps": ["Demonstrate direct mechanistic link between TREM2 signaling loss and senescence entry in human microglia","Establish whether senescence is upstream or downstream of other TREM2-related phenotypes (phagocytosis, lipid metabolism)","Compare microglial senescence profiles between TREM2 loss-of-function carriers and non-carriers using post-mortem tissue","Validate metabolic biomarkers in CSF as surrogate indicators of microglial TREM2 pathway activation"],"evidence_for": [{"claim": "TREM2 loss-of-function variants increase AD risk approximately 3-fold", "pmid": "29032277"}, {"claim": "TREM2 signaling regulates microglial survival, proliferation, and metabolic adaptation via PI3K/AKT and MAPK pathways", "pmid": "29032277"}, {"claim": "Microglial metabolism is dysregulated in neurodegenerative conditions", "pmid": "30047615"}],"evidence_against": [{"claim": "Impaired phagocytosis is an alternative downstream consequence of TREM2 dysfunction", "pmid": "30559476"}, {"claim": "Senescence pathway is one of several plausible mechanisms, not uniquely supported", "pmid": "31176459"}, {"claim": "Association between TREM2 variants and AD risk does not establish mechanistic causality", "pmid": "29032277"}],"verdict": "promising"}